The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve DMS can more efficiently decongest ADHF patients in comparison to Control Therapy.
2 Primary · 2 Secondary · Reporting Duration: Through study completion, an average of 90 days
100 Total Participants · 2 Treatment Groups
Primary Treatment: Reprieve Decongestion Management System · No Placebo Group · N/A
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: